Cary N. Robertson, MD
Department / Division
Surgery /
Urology
Address
3480 Wake Forest Road, Suite 506
Raleigh, NC 27609
Appointment Telephone
919-862-5600
Office Telephone
919-862-5600
Fax Telephone
919-681-8074
- MD, Tulane University School of Medicine (Louisiana), 1977
- Surgery, University of Oregon Health Center, 1977-1978
- Surgery, Duke University Medical Center, 1980-1981
- Urologic Surgery, Duke University Medical Center, 1981-1985
- Urologic Oncology (Fellow), Surgery Branch, National Cancer Institute (Maryland), 1985-1987
- Urologic Oncology (Senior Investigator), Surgery Branch, National Cancer Institute (Maryland), 1987-1988
Clinical Interests
Urologic oncology, robot-assisted laparoscopic radial prostatectomy, high-intensity focused ultrasound therapy of prostate cancer, renal-cell cancer, partial nephrectomy, benign prostatic hyperplasia
Research Interests
1. High Intensity Focused Ultrasound Therapy of Prostate Cancer
2. Surgical Technique Improvement in Prostate Cancer
3. Clinical Predictors of Outcome in Prostate Cancer
4. Molecular Imaging and Genomics of Genitourinary Malignancies
5. Quality of Life measures in Genitourinary Malignancies
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Aureon
- Aurora Funds
- EDAP Technomed, Inc
- Endo Pharmaceuticals
- Ortho Biotech (Johnson & Johnson)
Representative Publications
Mishel MH, Belyea M, Germino BB, Stewart JL, Bailey DE, Robertson CN, and Mohler J. Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects. Cancer 94(6): 1854-1866, 2002.
(2002)
Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002 Jul;168(1):273-80.
(2002)
Abstract
DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001 Jan 1;61(1):110-7.
(2001)
Abstract
Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001 Jul;58(1):47-52.
(2001)
Abstract
Ogawa Y, Nakagami Y, Ishizaki R, Yoshida H, Parkinson KM, Robertson CN, Paulson DF. Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1. Anticancer Res. 2001 Sep-Oct;21(5):3341-7.
(2001)
Abstract
Young MD, Dahm P, Robertson CN. Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy. J Urol. 2001 Sep;166(3):994.
(2001)
Abstract
Denmark-Wahnefried W, Schildkraut JM, Thompson D, Lesko SM, McIntyre L, Schwingl P, Paulson DF, Robertson CN, Anderson EE, Walther PJ. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):325-8.
(2000)
Abstract
Ahearn GS, Bedlack RS, Price DT, Robertson CN, Morgenlander JC. Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis. South Med J. 1999 Aug;92(8):809-11.
(1999)
Abstract
Kim SP, Bennett CL, Chan C, Chmiel J, Falcone D, Knight SJ, Kuzel T, Davis TC, Elstein AS, Moran E, Robertson CN, Smith JS. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Huntingt). 1999 Jun;13(6):823-32; discussion 835-8.
(1999)
Abstract
Padilla-Nash HM, Nash WG, Padilla GM, Roberson KM, Robertson CN, Macville M, Schröck E, Ried T. Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping. Genes Chromosomes Cancer. 1999 May;25(1):53-9.
(1999)
Abstract
